PA8631301A1 - Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central - Google Patents
Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso centralInfo
- Publication number
- PA8631301A1 PA8631301A1 PA20058631301A PA8631301A PA8631301A1 PA 8631301 A1 PA8631301 A1 PA 8631301A1 PA 20058631301 A PA20058631301 A PA 20058631301A PA 8631301 A PA8631301 A PA 8631301A PA 8631301 A1 PA8631301 A1 PA 8631301A1
- Authority
- PA
- Panama
- Prior art keywords
- treatment
- nervous system
- central nervous
- morfoline
- system disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
LA INVENCION SE REFIERE A COMPUESTOS DE FORMULAS l EN LAS QUE R1-R8, A, X, Y Z SE DEFINEN COMO EN LA MEMORIA DESCRIPTIVA, A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y A SU USO EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56724404P | 2004-04-30 | 2004-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8631301A1 true PA8631301A1 (es) | 2006-05-16 |
Family
ID=34965714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20058631301A PA8631301A1 (es) | 2004-04-30 | 2005-04-27 | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central |
Country Status (28)
Country | Link |
---|---|
US (1) | US7659394B2 (es) |
EP (1) | EP1745029A1 (es) |
JP (2) | JP4185154B2 (es) |
KR (1) | KR100943555B1 (es) |
CN (1) | CN1950348A (es) |
AP (1) | AP2006003771A0 (es) |
AR (1) | AR049335A1 (es) |
AU (1) | AU2005238296A1 (es) |
BR (1) | BRPI0510453A (es) |
CA (1) | CA2564994A1 (es) |
CR (1) | CR8718A (es) |
EA (1) | EA200601798A1 (es) |
EC (1) | ECSP066962A (es) |
GE (1) | GEP20084550B (es) |
GT (1) | GT200500097A (es) |
IL (1) | IL178648A0 (es) |
MA (1) | MA28555B1 (es) |
MX (1) | MXPA06012505A (es) |
NL (1) | NL1028924C2 (es) |
NO (1) | NO20065456L (es) |
PA (1) | PA8631301A1 (es) |
PE (1) | PE20060680A1 (es) |
SV (1) | SV2006002098A (es) |
TN (1) | TNSN06348A1 (es) |
TW (1) | TW200600506A (es) |
UY (1) | UY28876A1 (es) |
WO (1) | WO2005105763A1 (es) |
ZA (1) | ZA200608628B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL126999A (en) | 1996-07-24 | 2002-03-10 | Warner Lambert Co | Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
JP4185154B2 (ja) * | 2004-04-30 | 2008-11-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害治療用の置換モルホリン化合物 |
JP5268652B2 (ja) * | 2006-02-01 | 2013-08-21 | メルク・シャープ・アンド・ドーム・コーポレーション | カリウムチャンネルインヒビター |
EP1854785A1 (en) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
US7531519B2 (en) * | 2006-09-21 | 2009-05-12 | Medical And Pharmaceutical Industry Technology And Development Center | Polygalatenosides and use thereof as an antidepressant agent |
TW200846003A (en) * | 2007-03-15 | 2008-12-01 | Astellas Pharma Inc | Novel prophylactic and/or therapeutic agent for diabetic neuropathy |
TW200846002A (en) * | 2007-03-15 | 2008-12-01 | Astellas Pharma Inc | Novel prophylactic and/or therapeutic agent for diabetic neuropathy |
JP5384487B2 (ja) * | 2007-06-04 | 2014-01-08 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
US7888386B2 (en) | 2008-07-24 | 2011-02-15 | Theravance, Inc. | 3-(phenoxyphenylmethyl)pyrrolidine compounds |
NZ592413A (en) | 2008-11-14 | 2013-02-22 | Theravance Inc | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound |
EP2385938B1 (en) | 2009-01-12 | 2015-03-04 | Pfizer Limited | Sulfonamide derivatives |
US8474529B2 (en) * | 2009-04-09 | 2013-07-02 | Regency Technologies Llc | Control of concentric tubing direction |
AR075988A1 (es) * | 2009-04-09 | 2011-05-11 | Lilly Co Eli | Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico |
EP2419405A1 (en) * | 2009-04-15 | 2012-02-22 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
WO2011008666A2 (en) | 2009-07-13 | 2011-01-20 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
ES2495366T3 (es) | 2009-07-21 | 2014-09-17 | Theravance, Inc. | Compuestos de 3-fenoximetilpirrolidina |
AR077969A1 (es) | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
US8778949B2 (en) * | 2010-01-11 | 2014-07-15 | Theravance Biopharma R&D Ip, Llc | 1-(2-phenoxymethylphenyl)piperazine compounds |
JP5769348B2 (ja) * | 2010-03-22 | 2015-08-26 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | 1−(2−フェノキシメチルヘテロアリール)ピペリジン化合物および1−(2−フェノキシメチルヘテロアリール)ピペラジン化合物 |
EP2390248A1 (en) | 2010-05-24 | 2011-11-30 | Faes Farma, S.A. | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies |
CN103025714A (zh) | 2010-05-24 | 2013-04-03 | 飞思药物有限公司 | 用于治疗及预防淀粉样蛋白病理状态的氟芬辛衍生物 |
TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
TW201206893A (en) * | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
US8471040B2 (en) | 2010-10-11 | 2013-06-25 | Theravance, Inc. | Serotonin reuptake inhibitors |
WO2012075239A1 (en) | 2010-12-03 | 2012-06-07 | Theravance, Inc. | Serotonin reuptake inhibitors |
JP2012207995A (ja) * | 2011-03-29 | 2012-10-25 | Univ Of Fukui | 脳内ノルエピネフリン・トランスポータを標的とする放射性臭素標識pet分子イメージングプローブ |
EP2745876A1 (en) * | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
ES2819830T3 (es) | 2016-03-17 | 2021-04-19 | Hoffmann La Roche | Derivado de 5-etiol-4-metil-pirazol-3-carboxamida que tiene actividad como agonista de TAAR |
CA3159378A1 (en) | 2019-10-31 | 2021-05-06 | ESCAPE Bio, Inc. | Solid forms of an s1p-receptor modulator |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1138405A (en) * | 1966-12-28 | 1969-01-01 | Ici Ltd | Morpholine derivatives |
GB1260886A (en) * | 1969-06-20 | 1972-01-19 | Ici Ltd | Process for aryloxymethylmorpholine derivatives |
BE759013R (fr) | 1969-11-17 | 1971-05-17 | Ici Ltd | Derives de la |
BE758766A (fr) * | 1969-11-17 | 1971-05-10 | Ici Ltd | Nouveaux derives de la morpholine et de la |
US4116665A (en) * | 1976-04-02 | 1978-09-26 | Eli Lilly And Company | Method of regulating the growth of aquatic weeds with pyridine derivatives |
DE2715138B2 (de) | 1977-04-05 | 1980-02-07 | Forbach Gmbh & Co Kg, 8740 Bad Neustadt | Wasserbehälter aus Kunststoff fur einen Heißwasserbereiter |
IT1093255B (it) | 1978-01-20 | 1985-07-19 | Erba Carlo Spa | Derivati fenossialcanolaminici |
IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
CA1215067A (en) | 1982-10-18 | 1986-12-09 | Sudarshan K. Malhotra | 2-(6-phenoxy-3-nitro-2-pyridinoxy)-propionate compounds |
GB8419683D0 (en) * | 1984-08-02 | 1984-09-05 | Erba Farmitalia | 3-substituted derivatives of 1-amino-2-hydroxy-propane |
GB2167407B (en) * | 1984-11-22 | 1988-05-11 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
US4855143A (en) * | 1986-04-04 | 1989-08-08 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
US5750532A (en) * | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
US5272167A (en) * | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
FR2612926B1 (fr) | 1987-03-24 | 1989-06-09 | Adir | Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
FR2653999A1 (fr) | 1989-11-06 | 1991-05-10 | Adir | Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
JPH04185154A (ja) * | 1990-11-20 | 1992-07-02 | Nec Corp | 中継台接続制御方式 |
AU642582B2 (en) * | 1991-02-25 | 1993-10-21 | Eli Lilly And Company | Treatment of lower urinary tract disorders |
US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
US5559135A (en) | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
TW375612B (en) | 1995-04-06 | 1999-12-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same |
ATE240942T1 (de) | 1995-11-17 | 2003-06-15 | Merck & Co Inc | Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren |
UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
AU762726B2 (en) | 1998-03-31 | 2003-07-03 | Acadia Pharmaceuticals, Inc. | Compounds with activity on muscarinic receptors |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
SI1068194T1 (en) | 1998-04-01 | 2004-04-30 | Janssen Pharmaceutica N.V. | Pde iv inhibiting pyridine derivatives |
EP1104411A4 (en) * | 1998-08-12 | 2002-10-24 | Smithkline Beecham Corp | CALCILYTIC COMPOUNDS |
CN1249038C (zh) * | 1998-12-29 | 2006-04-05 | 法玛西雅厄普约翰美国公司 | 芳基醚的制备方法 |
CZ300551B6 (cs) | 1999-03-31 | 2009-06-17 | Janssen Pharmaceutica N. V. | Predželatinovaný škrob v rízene se uvolnující formulaci |
PT1459750E (pt) * | 1999-07-01 | 2005-08-31 | Pharmacia & Upjohn Co Llc | (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes |
CA2383466C (en) * | 1999-09-16 | 2009-08-25 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogen-containing 6-membered cyclic compounds |
WO2001044258A1 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Novel heterocycles |
IL150632A0 (en) | 2000-01-18 | 2003-02-12 | Pfizer Prod Inc | Corticotropin releasing factor antagonists |
US7273868B2 (en) * | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
US7220736B2 (en) | 2000-04-28 | 2007-05-22 | Tanabe Seiyaku Co., Ltd. | Pyrimidine compounds |
US20040048860A1 (en) | 2000-10-31 | 2004-03-11 | Jes Olesen | Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache |
WO2002053104A2 (en) * | 2001-01-02 | 2002-07-11 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
WO2003037338A2 (en) | 2001-11-01 | 2003-05-08 | Vertex Pharmaceuticals Incorporated | Modulators of the cholesterol biosynthetic pathway |
US6635675B2 (en) * | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
DE60223718T2 (de) * | 2001-12-11 | 2008-10-30 | Eli Lilly And Co., Indianapolis | Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
EP1465863B1 (en) | 2002-01-04 | 2008-07-09 | NeuroSearch A/S | Potassium channel modulators |
US20050009927A1 (en) * | 2002-01-23 | 2005-01-13 | Pfizer Inc | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
US6962932B2 (en) * | 2002-02-15 | 2005-11-08 | Schering Aktiengesellschaft | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
AU2003225837B2 (en) * | 2002-03-15 | 2008-11-06 | Forest Laboratories Holdings Limited | NE and 5-HT reuptake inhibitors for treating visceral pain syndromes |
GB0215392D0 (en) | 2002-07-03 | 2002-08-14 | Glaxo Group Ltd | Chemical compounds |
US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
AU2003255294A1 (en) | 2002-08-15 | 2004-03-11 | Sofitech N.V. | Use of distributed temperature sensors during wellbore treatments |
GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
ES2264028T3 (es) * | 2002-08-23 | 2006-12-16 | Eli Lilly And Company | Derivados de bencilmorfolina. |
ES2315525T3 (es) * | 2002-08-23 | 2009-04-01 | Eli Lilly And Company | Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina. |
WO2004048860A1 (fr) | 2002-11-27 | 2004-06-10 | Chabanov Alim I | Procede pour construire des installations energetiques solaires haute puissance |
JP2004189738A (ja) | 2002-11-29 | 2004-07-08 | Nippon Nohyaku Co Ltd | 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法 |
AU2003290363A1 (en) | 2002-12-24 | 2004-07-22 | Amedis Pharmaceuticals Ltd. | Therapeutic use of selective noradrenaline reuptake inhibitors |
TW200505902A (en) * | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
GB0319793D0 (en) * | 2003-08-22 | 2003-09-24 | Lilly Co Eli | Pyridinylmorpholine derivatives |
EP1660064A2 (en) | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
US20060241188A1 (en) | 2003-08-27 | 2006-10-26 | Elililly And Company | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors |
EP1660185A2 (en) | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors |
EP1675582A1 (en) * | 2003-09-12 | 2006-07-05 | Warner-Lambert Company LLC | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
DE602004019698D1 (de) | 2003-12-23 | 2009-04-09 | Lilly Co Eli | Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin |
DE102004005545B4 (de) | 2004-02-04 | 2018-10-31 | Siemens Healthcare Gmbh | Verbindungsanordnung und Flachbaugruppe |
GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
JP4185154B2 (ja) * | 2004-04-30 | 2008-11-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害治療用の置換モルホリン化合物 |
-
2005
- 2005-04-19 JP JP2007510153A patent/JP4185154B2/ja not_active Expired - Fee Related
- 2005-04-19 AP AP2006003771A patent/AP2006003771A0/xx unknown
- 2005-04-19 CN CNA2005800137766A patent/CN1950348A/zh active Pending
- 2005-04-19 MX MXPA06012505A patent/MXPA06012505A/es unknown
- 2005-04-19 KR KR1020067022767A patent/KR100943555B1/ko not_active IP Right Cessation
- 2005-04-19 BR BRPI0510453-0A patent/BRPI0510453A/pt not_active IP Right Cessation
- 2005-04-19 GE GEAP20059682A patent/GEP20084550B/en unknown
- 2005-04-19 WO PCT/IB2005/001158 patent/WO2005105763A1/en active Application Filing
- 2005-04-19 AU AU2005238296A patent/AU2005238296A1/en not_active Abandoned
- 2005-04-19 EP EP05733459A patent/EP1745029A1/en not_active Withdrawn
- 2005-04-19 CA CA002564994A patent/CA2564994A1/en not_active Abandoned
- 2005-04-19 EA EA200601798A patent/EA200601798A1/ru unknown
- 2005-04-27 PA PA20058631301A patent/PA8631301A1/es unknown
- 2005-04-28 AR ARP050101667A patent/AR049335A1/es unknown
- 2005-04-28 UY UY28876A patent/UY28876A1/es not_active Application Discontinuation
- 2005-04-28 PE PE2005000480A patent/PE20060680A1/es not_active Application Discontinuation
- 2005-04-28 GT GT200500097A patent/GT200500097A/es unknown
- 2005-04-29 TW TW094113971A patent/TW200600506A/zh unknown
- 2005-04-29 SV SV2005002098A patent/SV2006002098A/es not_active Application Discontinuation
- 2005-04-29 NL NL1028924A patent/NL1028924C2/nl not_active IP Right Cessation
- 2005-04-29 US US11/119,210 patent/US7659394B2/en not_active Expired - Fee Related
-
2006
- 2006-10-16 IL IL178648A patent/IL178648A0/en unknown
- 2006-10-16 ZA ZA200608628A patent/ZA200608628B/xx unknown
- 2006-10-27 TN TNP2006000348A patent/TNSN06348A1/fr unknown
- 2006-10-27 CR CR8718A patent/CR8718A/es not_active Application Discontinuation
- 2006-10-30 MA MA29418A patent/MA28555B1/fr unknown
- 2006-10-30 EC EC2006006962A patent/ECSP066962A/es unknown
- 2006-11-27 NO NO20065456A patent/NO20065456L/no not_active Application Discontinuation
-
2007
- 2007-09-07 JP JP2007233201A patent/JP2008019267A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA200608628B (en) | 2009-01-28 |
BRPI0510453A (pt) | 2007-10-30 |
MXPA06012505A (es) | 2006-12-15 |
KR20070006881A (ko) | 2007-01-11 |
UY28876A1 (es) | 2005-11-30 |
GEP20084550B (en) | 2008-11-25 |
SV2006002098A (es) | 2006-02-15 |
IL178648A0 (en) | 2007-02-11 |
JP2008019267A (ja) | 2008-01-31 |
CR8718A (es) | 2007-07-24 |
US7659394B2 (en) | 2010-02-09 |
AP2006003771A0 (en) | 2006-10-31 |
CN1950348A (zh) | 2007-04-18 |
EP1745029A1 (en) | 2007-01-24 |
US20050245519A1 (en) | 2005-11-03 |
TW200600506A (en) | 2006-01-01 |
WO2005105763A1 (en) | 2005-11-10 |
JP4185154B2 (ja) | 2008-11-26 |
NO20065456L (no) | 2007-01-04 |
KR100943555B1 (ko) | 2010-02-22 |
JP2007535530A (ja) | 2007-12-06 |
TNSN06348A1 (fr) | 2008-02-22 |
CA2564994A1 (en) | 2005-11-10 |
ECSP066962A (es) | 2006-12-20 |
PE20060680A1 (es) | 2006-08-11 |
AU2005238296A1 (en) | 2005-11-10 |
EA200601798A1 (ru) | 2007-04-27 |
GT200500097A (es) | 2005-12-12 |
AR049335A1 (es) | 2006-07-19 |
NL1028924C2 (nl) | 2006-04-27 |
NL1028924A1 (nl) | 2005-11-01 |
MA28555B1 (fr) | 2007-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8631301A1 (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central | |
PA8609701A1 (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
GT200600159A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
UY29781A1 (es) | Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos | |
CO6331473A2 (es) | Derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetilo como antagonistas alfa2c para uso en el tratamiento de enfermedades del sistema nervioso central y periferico | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
DOP2006000061A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
UY29633A1 (es) | Derivados de oxindol | |
UY30327A1 (es) | Nuevos compuestos ii | |
GT200600166A (es) | Derivados de cromano y cromeno y usos de los mismos | |
CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
UY30835A1 (es) | 8-alquinilxantinas y derivados | |
UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
ECSP088366A (es) | 1,2-diarilimidazoles para uso como moduladores de cb1 | |
CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
CR9407A (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
UY29804A1 (es) | Quinolinas de alquilnitrilo | |
UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
PA8720601A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos | |
CR7735A (es) | Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
UY29734A1 (es) | Piperazinas bicíclicas como antagonistas de receptores de glutamato metabotrópicos | |
UY31522A1 (es) | Nanoparticulas con superficie modificada | |
UY28656A1 (es) | Derivados de indano heterocíclicos sustituidos y compuestos relacionados para el tratamiento de esquizofrenia |